Filtered By:
Condition: Hemorrhagic Stroke
Management: Medicare

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 103 results found since Jan 2013.

Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: A dose subgroup analysis of the ARISTOPHANES Study
ConclusionsAmong NVAF pts, both standard- and lower-dose api pts had lower rates of MB compared to corresponding doses of dabi and riva, respectively; both doses of api demonstrated lower rates of S/SE vs. corresponding doses of riva. The comparisons between dabi and riva showed varying results for S/SE and MB across dosage levels. Dose selection criteria cannot be ascertained from the current data sources. Future studies of pts who were appropriately dosed are warranted.
Source: Archives of Cardiovascular Diseases Supplements - December 25, 2018 Category: Cardiology Source Type: research

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: The dose subgroup analysis of the ARISTOPHANES study
ConclusionsIn this large observational study, api was the only NOAC associated with lower rates of S/SE and MB for both doses compared to warf. Dose selection criteria cannot be ascertained from current data sources. Future studies of pts who were appropriately dosed should be warranted.
Source: Archives of Cardiovascular Diseases Supplements - December 25, 2018 Category: Cardiology Source Type: research

Impact of Complications on Resource Utilization During 90-Day Coronary Artery Bypass Graft Bundle for Medicare Beneficiaries
ConclusionsMedicare beneficiaries who have adverse events during their index CABG hospitalization will significantly affect that hospital’s financial risk. The challenge under the voluntary CABG bundled payment program will be to monitor and reduce adverse events and manage the services consumed by Medicare beneficiaries having adverse events delivered at all the venues of care.
Source: The Annals of Thoracic Surgery - April 21, 2019 Category: Cardiovascular & Thoracic Surgery Source Type: research

Comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants and warfarin in older adults with atrial fibrillation and diabetes.
CONCLUSION: Oral anticoagulation therapy with NOACs was found to be more effective than warfarin therapy among older adults with NVAF and comorbid DM. PMID: 33327796 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - December 18, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Epidemiology of cerebral venous sinus thrombosis and cerebral venous sinus thrombosis with thrombocytopenia in the United States, 2018 and 2019
CONCLUSIONS: Our findings provide recent and comprehensive data on the epidemiology of CVST and CVST with thrombocytopenia.PMID:35284775 | PMC:PMC8901465 | DOI:10.1002/rth2.12682
Source: Thrombosis and Haemostasis - March 14, 2022 Category: Hematology Authors: Amanda B Payne Alys Adamski Karon Abe Nimia L Reyes Lisa C Richardson William Craig Hooper Laura A Schieve Source Type: research

Abstract 243: Impact of Dual Health Care System Use on Quality of Warfarin Anticoagulation in Atrial Fibrillation Poster Session II
Conclusion: More than half of Veterans age ≥ 65 with AF and VA-issued warfarin receive outpatient INR testing in MC. Dual health care system use is associated with lower achievement of process measures of quality of anticoagulation care, which could affect outcomes of stroke, hemorrhage and death.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Than, C., Xu, X., Schmitt, S., Frayne, S., Phibbs, C., Holmes, T., Heidenreich, P., Moos, R., Berlowitz, D., Go, A., Turakhia, M. Tags: Poster Session II Source Type: research

Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer.
CONCLUSION: Our study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed. PMID: 24002522 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - September 3, 2013 Category: Cancer & Oncology Authors: Hershman DL, Wright JD, Lim E, Buono DL, Tsai WY, Neugut AI Tags: J Clin Oncol Source Type: research

Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer Health Services and Outcomes
Conclusion Our study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed.
Source: Journal of Clinical Oncology - September 27, 2013 Category: Cancer & Oncology Authors: Hershman, Wright, Lim, Buono, Tsai, Neugut Tags: Quality of Care, Quality of Care Health Services and Outcomes Source Type: research

Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease
Conclusions: ADPKD is a significant risk factor for ICH among patients on maintenance dialysis. Our Medicare primary cohort was older than in previous studies of intracranial aneurysm rupture among ADPKD patients. There are also limitations inherent to using the USRDS database.
Source: BioMed Central - February 26, 2014 Category: Journals (General) Authors: David J YooLawrence AgodoaChristina M YuanKevin C AbbottRobert Nee Source Type: research

Use of the Corus® CAD Gene Expression Test for Assessment of Obstructive Coronary Artery Disease Likelihood in Symptomatic Non-Diabetic Patients
Conclusions The Corus CAD test has been extensively evaluated since it was first derived, including with two prospective multi-center trials. Given the scope of the deleterious effects of CAD and the considerable costs involved in diagnosing obstructive CAD, a blood test that can help in this determination is certainly valuable. The Corus CAD test promises to have an important role in this regard particularly if it continues to perform this well in larger, more diverse cohorts.
Source: PLOS Currents Evidence on Genomic Tests - August 26, 2013 Category: Genetics & Stem Cells Authors: Jose Vargas Source Type: research

Racial and ethnic differences in mortality and cardiovascular events among patients with end‐stage renal disease due to lupus nephritis
Conclusion: Among patients with LN ESRD, Asians and Hispanics experienced lower mortality and CV event risks, while African Americans had higher mortality and CV event risks compared to Whites. This article is protected by copyright. All rights reserved.
Source: Arthritis Care and Research - January 1, 2015 Category: Rheumatology Authors: Jose A. Gómez‐Puerta, Candace H. Feldman, Graciela S. Alarcón, Hongshu Guan, Wolfgang C. Winkelmayer, Karen H. Costenbader Tags: Original Article Source Type: research

Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients With Atrial Fibrillation
ConclusionsOlder adults with atrial fibrillation rarely have absolute contraindications to oral anticoagulation therapy. Among patients without contraindications, most appeared to be eligible for any anticoagulant, and relatively high‐risk features appeared not to influence warfarin use.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - April 1, 2015 Category: Cardiology Authors: Benjamin A. Steinberg, Melissa A. Greiner, Bradley G. Hammill, Lesley H. Curtis, Emelia J. Benjamin, Susan R. Heckbert, Jonathan P. Piccini Tags: Original Research Article Source Type: research

Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin.
In conclusion, we developed a HF severity model using easily available clinical characteristics that performed well to risk-stratify patients with HF who are receiving anticoagulation for AF with regard to major haemorrhage. PMID: 25948532 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 7, 2015 Category: Hematology Authors: Kim EJ, Ozonoff A, Hylek EM, Berlowitz DR, Ash AS, Miller DR, Zhao S, Reisman JI, Jasuja GK, Rose AJ Tags: Thromb Haemost Source Type: research

Statins and subarachnoid hemorrhage in Medicare patients with unruptured cerebral aneurysms
ConclusionsStatin use by patients with unruptured cerebral aneurysms was not associated with subarachnoid hemorrhage risk. Given the prior animal experimental studies demonstrating a protective effect, further prospective studies are needed to investigate the potential relationship.
Source: International Journal of Stroke - June 29, 2015 Category: Neurology Authors: Kimon Bekelis, Jeremy Smith, Weiping Zhou, Todd A. MacKenzie, David W. Roberts, Jonathan Skinner, Nancy E. Morden Tags: Research Source Type: research

MassDevice.com +3 | The top 3 medtech stories for August 17, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. CooperSurgical pays $47m for IVF screener Reprogenetics Cooper Cos. CooperSurgical subsidiary acquired in-vitro fertilization screening company Reprogenetics for nearly $47 million. Livingston, N.J.-based Reprogenetics offers pre-implantation genetic screening and diagnosis for in vitro fertil...
Source: Mass Device - August 17, 2015 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 3 Source Type: news